Public data, as of October 2026

Company profile

Royalty Pharma plc

RPRXroyaltypharma.comLatest disclosure 2024

The Data Hub holds reported emissions for 2024, but one or more scopes are still missing.

Is this your company? Claim it

SBTi status

No SBTi record is linked to this company yet.

Where insetting fits

Scope 3 appears once a full disclosure is matched.

Peer position

A peer comparison appears once sector peers report their emissions.

Voluntary retirements

No voluntary retirement names this company as beneficiary yet.

Emissions

How the reported footprint breaks down by scope and year.

tCO₂e, GHG Protocol scopes
Source: published disclosure, FY2024

Peer benchmark

How Royalty Pharma plc compares with its industry peers on Scope 3.

Peers: companies in the broad registry sector "Pharmaceuticals". No SBTi industry is linked yet, so treat this as a rough comparison.

CompanyScope 3 share%

Royalty Pharma plcThis companyScope 3 share
Merck KGaA81%

Company profile

A claimed profile keeps the figures accurate and shows the company’s projects.

Claiming is free. Your team can correct data, add newer disclosures and list reduction projects from your value chain, so that customers and suppliers can co-fund them.

Claim this profile Talk to Carbon3

1
Confirm employment at the company

Related projects

None yet

Inset projects on Carbon3None yet

Reported emissions by year

Scope 1
Scope 2
Scope 3

One or more scopes for this year are not matched yet, so the total is not shown.

Years without a matched disclosure stay open until a published source is matched.

Source document: royaltypharma.com

Scope 3 by category, 2024

1 categories itemized

C15InvestmentsLargest category23 kt100%

Climate targets

What the SBTi listing says about the company's targets.

Status as published by the SBTi

No science-based target on record for this company

Carbon3 has not matched this company to an entry in the public SBTi target dataset. Companies that SBTi adds to its dataset appear here after the next daily update.

Voluntary retirements

Voluntary credits retired for this company on public registries.

Registry records naming the company as beneficiary

No voluntary credit retirements linked to this company

Carbon3 has not found a retirement in the public voluntary carbon market registry data it tracks that names this company as the beneficiary.

Roche Holding AG

96%

Cipla Limited95%

Teva Pharmaceutical Industries Ltd.90%

Daiichi Sankyo Company, Limited97%

Takeda Pharmaceutical Company Limited93%

Peer median: 94%Scope 3 boundaries differ between reports, so compare shares with care.

Scope 3 position

No peer median yet

The median appears when at least one peer reports all three scopes.

Disclosure coverage

6 of 6 disclose

6 of 6 named peers report all three scopes, so their Scope 3 share can be compared.

Research summary

What the public record says about this company's decarbonization.

No report has been generated for this company yet

Anyone can read a cached company report, while generating a new one can take a few minutes and needs a free account.

Related projects

Decarbonization projects that name the company as a partner.

Emerging projects catalog, status as reported by each project

No projects linked to this company yet

Carbon3 has not yet found a public decarbonization project that names this company.

No inset projects are listed for this company yet.

Suppliers to Royalty Pharma plc can list a reduction project on Carbon3 at no cost, so that the company could co-fund it.

List a supplier project

Sign in with an email address at the company's own domain.

2

Review the data

Flag corrections and upload newer disclosures, which Carbon3 checks against a published source.

3

List a project at no cost

Turn verified supply-chain reductions into inset credits that partners can co-fund.

A free account also gives access to downloads, alerts and new research reports.